Transuranic actinide (TRU) (TRU)

Transuranic actinides are radioactive chemical elements with atomic numbers greater than 92, such as plutonium, americium, and curium, which are primarily anthropogenic products of nuclear reactors (Wikipedia, 2024). These elements pose significant health risks due to their high radiotoxicity and chemical toxicity, often depositing in the bone and liver where they can cause osteosarcoma and other malignancies (Taylor, 1989). In biological systems, they often mimic essential metal ions; for example, plutonium(IV) shares transport pathways with iron(III), binding to transferrin for systemic distribution (PubMed: 15667106). They are not endogenous therapeutic targets but are the focus of decorporation therapy, which aims to remove them from the body to prevent radiation-induced damage. The primary pharmacological intervention involves chelating agents like diethylenetriaminepentaacetic acid (DTPA), which sequester the metal ions into stable complexes for urinary excretion (CDC, 2018).

Other names

Transuranium elementsTransuranicsHeavy radionuclidesTransuranic elements

Chelation therapy: The drugs act as chelating agents that provide multiple donor atoms to bind with the actinide ions, forming stable, water-soluble complexes that are readily excreted from the body via the kidneys, thereby reducing the radiation dose to internal organs (CDC, 2018; PubMed: 15667106).